Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Immunovaccine's phase I/II DPX-Survivac testing will target ovarian cancer

Nov. 22, 2010

Spanish scientists present new inhibitors of PI3K/mTOR

Nov. 22, 2010

New HIF-1-alpha inhibitor P-2630 demonstrates oncolytic activity in vivo

Nov. 22, 2010

Lilly describes activity of LY-2606368, now in phase I testing

Nov. 22, 2010

BioSante Pharma sells Cold Genesys rights to its oncolytic virus technology

Nov. 22, 2010

Reolysin to enter phase I trial in pediatric patients with solid tumors

Nov. 19, 2010

Astex Therapeutics claims new fibroblast growth factor receptor inhibitors

Nov. 19, 2010

Ipsen Pharma identifies new imidazolidine-2,4-dione derivatives for prostate cancer

Nov. 19, 2010

Morphotek and Hokkaido University join to evaluate amatuximab for pancreatic cancer

Nov. 19, 2010

Aveo Pharma advances phase Ib tivozanib/capecitabine combination trial

Nov. 19, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...